Drugs / EPO-018B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02366325 | Jul 2014 → Dec 2015 | anemia, chronic renal failure syndrome | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02403362 | Jun 2014 → Oct 2015 | anemia, chronic renal failure syndrome | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPO-018B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02403362 ↗ |
| Known as | Pegol-Sihematide | “A Phase 2, Open-Label, Multi-Center , Dose-Ranging Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With Chronic Kidney...” NCT02403362 ↗ |
| Route | Intravenous | “multiple intravenous doses of EPO-018B” NCT02366325 ↗ |